The biopharmaceutical company has secured $49m in an oversubscribed series D.
Otonomy, a biopharmaceutical company focused on therapeutics for diseases and disorders of the inner and middle ear, has secured $49 in its series D. The round was oversubscribed and included new investors Jennison Associates, Perceptive Advisors, Federated Kaufmann Funds, Ally Bridge Group, as well as private investment funds advised by Clough Capital Partners and undisclosed institutional investors.
All existing investors also participated in the round, including OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture…